Background
==========

The hallmark of brain inflammation is the activation of glia, particularly microglia, the resident immune cells of the brain \[[@B1]\]. Microglia activation in brain pathologies, as caused by infectious diseases, inflammation, trauma, brain tumors, ischemia and AIDS, may result in neuronal injury and ultimately neurodegeneration \[[@B1]\]. Similar to other tissue macrophages, when microglia become activated they release potentially neurotoxic mediators \[[@B2]\], followed by sublethal and lethal injury to the central nervous system. The two different phenotypic forms of microglia, namely the activated but nonphagocytic microglia found in inflammatory pathologies and the reactive or phagocytic microglia present in trauma, infection and neuronal degeneration, appear to have the capacity to express cell-surface receptors and release mediators of inflammation, such as cytokines, coagulation factors, complement factors, proteases, nitric oxide, eicosanoids and reactive oxygen species \[[@B2]\].

Over the last three decades, the marine environment has been demonstrated to be a source of novel therapeutic agents, many of which have anti-inflammatory properties \[[@B3]\]. We have previously shown that selected marine natural products modulate eicosanoids \[[@B4],[@B5]\] and O~2~^-^generation from activated rat \[[@B6]\] and human neutrophils \[[@B7]\], as well as liver \[[@B8]\] and alveolar macrophages \[[@B9]\]. Based on these observations we hypothesized that selected marine natural products might potentially attenuate activated brain microglia \[[@B2]\]. Since the discovery by Sakai and Higa that the marine sponge-derived manzamine A (MZA) had potent antitumor activity \[[@B10]\], there has been a sustained interest in the chemistry \[[@B11]\] as well as the pharmacology of the manzamines, a class of β-carboline marine-derived alkaloids. More than 40 manzamine-type alkaloids have been isolated from 9 different genera of marine sponges from the Indian and Pacific Oceans, and in addition to the antitumor activity \[[@B10]\], manzamines have been shown to be immunostimulatory \[[@B12]\], insecticidal \[[@B13]\], antibacterial\[[@B13]\], antimalarial \[[@B14]\], antiparasitic \[[@B15]\], antiviral \[[@B16]\] and to possess antituberculosis activity \[[@B17]\].

In preliminary communications we have reported that MZA, isolated from the Okinawan marine sponge *Haliclona*sp., potently inhibited TXB~2~and O~2~^-^generation by activated rat neonatal microglia while showing very low concomitant toxicity \[[@B18]-[@B20]\]. We now extend these previous communications by reporting the results of a structure-activity relationship study with manzamines A, B, C, D, E and F on agonist-stimulated release of O~2~^-^and TXB~2~from LPS-activated rat neonatal microglia.

Results
=======

Effect of manzamine A on LPS-activated neonatal brain microglia TXB~2~, O~2~^-^and LDH release
----------------------------------------------------------------------------------------------

As shown in Fig. [1](#F1){ref-type="fig"}, MZA has a pentacyclic diamine group attached to the β-carboline moiety and it was tested as its hydrochloride salt. As is shown in Fig. [2A](#F2){ref-type="fig"}, MZA potently inhibited PMA-stimulated TXB~2~generation (IC~50~= 0.016 μM), with a maximum 95.5 % inhibition observed at 10 μM (MZA vs. vehicle, respectively 78.3 ± 45 vs. 1,413 ± 439 pg of TXB~2~per 200,000 microglia per 70 min, P \< 0.01, n = 4). Furthermore, as depicted in Fig. [3A](#F3){ref-type="fig"}, MZA inhibited PMA-stimulated O~2~^-^generation with an apparent IC~50~= 0.1 μM (MZA vs. vehicle, respectively 7.5 ± 1.8 vs.13.8 ± 1.9 nmol of O~2~^-^per 200,000 microglia per 70 min, P \< 0.01, n = 4). Significantly, increasing MZA concentrations to 10 μM resulted in O~2~^-^inhibition of 55.9 ± 6.1 %, P \< 0.01, n = 4.

![**The chemical structures of manzamines A, B, C, D, E and F.**Manzamines are indole-derived alkaloids isolated from the marine sponges *Haliclona sp*. \[10\], *Amphimedon sp*. \[66\] and *Xestospongia sp*. \[10,67\]. Molecular weights are respectively = 585.2, 550.8, 347.5, 591.3, 564.7, 580.8.](1471-2210-5-6-1){#F1}

![**Differential effects of manzamines A, B, C, D, E and F on PMA and OPZ-stimulated TXB~2~generation by LPS-activated rat neonatal microglia**. Rat neonatal microglia (200,000 cells/well) were activated with LPS (0.3 ng/mL) for 17 hours. Manzamines were added 15 min before stimulation with either PMA (1 μM) or OPZ (0.5 mg/mL). After 70 min, agonist-triggered TXB~2~was measured as described in *Materials and Methods*. LDH release, indicator of cytotoxicity, was determined as described in *Materials and Methods*. Data are expressed as percentage of control TXB~2~release triggered by either PMA (MZA: 1,423 ± 439 pg TXB~2~/70 min; MZB, C, D, E, F: 3,279 ± 281 pg TXB~2~/70 min), or OPZ (4,504 ± 308 pg TXB~2~/70 min). Data show mean ± SEM of indicated number (n) of experiments. \* P \< 0.05, \*\* P \< 0.01.](1471-2210-5-6-2){#F2}

![**Differential effects of manzamines A, B, C, D, E and F on PMA and OPZ-stimulated O~2~^-^generation by LPS-activated rat neonatal microglia**. Rat neonatal microglia (200,000 cells/well) were activated with LPS (0.3 ng/mL) for 17 hours. Manzamines were added 15 min before stimulation with either PMA (1 μM) or OPZ (0.5 mg/mL). After 70 min, agonist-triggered O~2~^-^release was determined as described in *Materials and Methods*. LDH release, indicator of cytotoxicity, was measured as described in *Materials and Methods*. Data are expressed as percentage of control O~2~^-^release triggered by PMA (MZA: 13.8 ± 1.9 nmoles O~2~^-^/70 min; MZB, C, D, E, F: 10.8 ± 0.6 nmoles O~2~^-^/70 min), or OPZ (9.4 ± 0.7 nmoles O~2~^-^/70 min). Data show mean ± SEM of indicated number (n) of experiments. \* P \< 0.05, \*\* P \< 0.01.](1471-2210-5-6-3){#F3}

In contrast, as shown in Fig. [2A](#F2){ref-type="fig"}, the effect of MZA on OPZ-stimulated TXB~2~generation was weaker (apparent IC~50~= 3.16 μM), with a maximum 58 % inhibition at 10 μM (MZA vs. vehicle, respectively 1,927 ± 474 vs. 4,504 ± 308 pg of TXB~2~per 200,000 microglia per 70 min, P \< 0.05, n = 2). Similarly, as depicted in Fig [3A](#F3){ref-type="fig"}, MZA did not appear to affect OPZ-stimulated O~2~^-^generation even at 10 μM (MZA vs. vehicle, respectively 9.5 ± 1 vs. 9.4 ± 0.7 O~2~^-^nmol per 200,000 microglia per 70 min, P \> 0.05, n = 2).

As shown in Fig. [2A](#F2){ref-type="fig"} and [3A](#F3){ref-type="fig"}, the cytotoxicity of MZA to neonatal brain microglia measured as LDH release was not significantly different from controls even at 10 μM (MZA vs. vehicle, respectively 21.3 ± 7 % vs. 13.9 ± 3.7 % of total LDH released by 0.1 % Triton X-100 treated-microglia, n = 6, P = 0.1735). This data suggests that the effect of MZA on both PMA-stimulated TXB~2~and O~2~^-^may be of a pharmacological nature.

Effect of manzamine B on LPS-activated neonatal brain microglia TXB~2~, O~2~^-^and LDH release
----------------------------------------------------------------------------------------------

MZB differs from MZA in having a tetracyclic diamine complex and an epoxide ring system (Fig. [1](#F1){ref-type="fig"}). As shown in Fig. [2B](#F2){ref-type="fig"}, MZB which was tested as a free base, was less potent than MZA in affecting PMA-stimulated TXB~2~generation (IC~50~= 1.6 μM). MZB 10 μM reduced TXB~2~release to 15.5 % of control (MZB vs. vehicle, respectively 546.3 ± 281 vs. 3,279 ± 281 pg of TXB~2~per 200,000 microglia per 70 min, P \< 0.01, n = 3). Similarly, as depicted in Fig. [3B](#F3){ref-type="fig"}, MZB was less potent than MZA in affecting PMA-stimulated O~2~^-^generation (IC~50~= 3.16 μM). MZB 10 μM reduced O~2~^-^release to 20 % of control (MZB vs. vehicle, respectively 2.14 ± 2.14 vs. 10.8 ± 0.6 nmol of O~2~^-^per 200,000 microglia per 70 min, P \< 0.01, n = 3).

As shown in Fig. [2B](#F2){ref-type="fig"}, MZB affected OPZ-stimulated TXB~2~(IC~50~= 1.44 μM) more than MZA. MZB 10 μM reduced TXB~2~generation to 25.6 % of control (MZB vs. vehicle, respectively 1,160 ± 207 vs. 4,504 ± 308 pg of TXB~2~per 200,000 microglia per 70 min, P \< 0.05, n = 2). Furthermore, as shown in Fig. [3B](#F3){ref-type="fig"}, MZB reduced OPZ-stimulated O~2~^-^generation (IC~50~= 4.17 μM) more than MZA. MZB 10 μM reduced O~2~^-^generation to 16.5 % of control (MZB vs. vehicle, respectively 1.5 ± 0.7 vs. 9.4 ± 0.7 O~2~^-^nmol per 200,000 microglia per 70 min, P \< 0.01, n = 2).

As shown in Fig. [2B](#F2){ref-type="fig"} and [3B](#F3){ref-type="fig"}, in contrast to MZA, MZB was cytotoxic to neonatal brain microglia at concentrations above 1 μM. In fact, considerable LDH release was observed at 10 μM (88.3 ± 12 % of total LDH released by 0.1 % Triton X-100 treated-microglia, n = 5, P \< 0.01). Taken together, these data suggest that the reduction of both O~2~^-^and TXB~2~generation resulted from both pharmacological and toxic effects of MZB on LPS-activated microglia cells.

Effect of manzamine C on LPS-activated neonatal brain microglia TXB~2~, O~2~^-^and LDH release
----------------------------------------------------------------------------------------------

MZC differs from MZA in having a monocyclic amine ring attached to the β-carboline moiety (Fig. [1](#F1){ref-type="fig"}). As shown in Fig. [2C](#F2){ref-type="fig"}, MZC which was tested as a free base, was less potent than MZA in affecting PMA-stimulated TXB~2~generation (IC~50~= 2.98 μM). MZC 10 μM reduced TXB~2~release to 19.6 % of control (MZC vs. vehicle, respectively 677 ± 293 vs. 3,279 ± 281 pg of TXB~2~per 200,000 microglia per 70 min, P \< 0.01, n = 3). Similarly, as depicted in Fig. [3C](#F3){ref-type="fig"}, MZC was less potent than MZA in affecting PMA-stimulated O~2~^-^generation (apparent IC~50~= 3.43 μM). MZC 10 μM reduced O~2~^-^release to 36.1 % of control (MZC vs. vehicle, respectively 3.7 ± 2.2 vs.10.8 ± 0.6 nmol of O~2~^-^per 200,000 microglia per 70 min, P \< 0.05, n = 3).

As shown in Fig. [2C](#F2){ref-type="fig"}, MZC affected OPZ-stimulated TXB~2~(IC~50~= 3.34 μM), similar to MZA. MZC 10 μM reduced TXB~2~generation to 29.8 % of control (MZC vs. vehicle, respectively 1,345 ± 160 vs. 4,504 ± 308 pg of TXB~2~per 200,000 microglia per 70 min, P \< 0.05 n = 2). Furthermore, as depicted in Fig. [3C](#F3){ref-type="fig"}, MZC reduced OPZ-stimulated O~2~^-^generation (apparent IC~50~= 9.3 μM), higher than MZA. MZC 10 μM reduced O~2~^-^generation to 41.6 % of control (MZC vs. vehicle, respectively 3.9 ± 0.3 vs. 9.4 ± 0.7 O~2~^-^nmol per 200,000 microglia per 70 min, P \< 0.05, n = 2).

As shown in Fig. [2C](#F2){ref-type="fig"} and [3C](#F3){ref-type="fig"}, and in contrast to MZA, MZC was cytotoxic to neonatal brain microglia though not as much as MZB. Substantial LDH release was observed at 10 μM (59.8 ± 11 % of total LDH released by 0.1 % Triton X-100 treated-microglia, n = 5, P \< 0.05). In summary, similar to MZB, the data suggests that the reduction of both O~2~^-^and TXB~2~generation resulted from both pharmacological and toxic effects of MZC on LPS-activated microglia cells.

Effect of manzamine D on LPS-activated neonatal brain microglia TXB~2~, O~2~^-^and LDH release
----------------------------------------------------------------------------------------------

MZD differs from MZA in having a tetrahydrocarboline group in the molecule (Fig. [1](#F1){ref-type="fig"}). As shown in Fig. [2D](#F2){ref-type="fig"}, MZD that was tested as its hydrochloride salt, strongly affected PMA-stimulated TXB~2~generation (IC~50~= 0.23 μM). MZD 10 μM reduced TXB~2~release to 18.8 % of control (MZD vs. vehicle, respectively 611 ± 342 vs. 3,279 ± 281 pg of TXB~2~per 200,000 microglia per 70 min, P \< 0.01, n = 3). Furthermore, as shown in Fig. [3D](#F3){ref-type="fig"}, MZD also strongly affected PMA-stimulated O~2~^-^generation. MZD 0.1 μM reduced O~2~^-^release to 14 % of control (MZD vs. vehicle, respectively 0.7 ± 0.7 vs. 10.8 ± 0.6 nmol of O~2~^-^per 200,000 microglia per 70 min, P \< 0.01, n = 3).

In contrast, as shown in Fig. [2D](#F2){ref-type="fig"} the effect of MZD on OPZ-stimulated TXB~2~generation was limited. MZD 10 μM reduced TXB~2~generation to 79.9% of control (MZD vs. vehicle, respectively 3,613 ± 469 vs. 4,504 ± 308 pg of TXB~2~per 200,000 microglia per 70 min, P \> 0.05, n = 2). Furthermore, as shown in Fig. [3D](#F3){ref-type="fig"}, MZD did not affect OPZ-stimulated O~2~^-^generation even at 10 μM.

As shown in Fig. [2D](#F2){ref-type="fig"} and [3D](#F3){ref-type="fig"}, and in contrast to MZB and C, MZD was very cytotoxic to microglia when PMA was used as an agonist to trigger O~2~^-^and TXB~2~release: MZD at 0.1 μM caused 61.5 ± 13 % of total LDH released by 0.1 % Triton X-100 treated-microglia (n = 5, P \< 0.05). In contrast to the limited effect of MZD on OPZ-stimulated microglia, the data suggests that the reduction of PMA-stimulated O~2~^-^and TXB~2~generation resulted from both pharmacological and toxic effects of MZD on LPS-activated microglia cells.

Effect of manzamine E on LPS-activated neonatal brain microglia TXB~2~, O~2~^-^and LDH release
----------------------------------------------------------------------------------------------

As shown in Fig. [1](#F1){ref-type="fig"}, MZE differs from MZA in having a saturated ketone functionality in the eight-membered amine ring. As depicted in Fig. [2E](#F2){ref-type="fig"}, MZE inhibited PMA-stimulated TXB~2~generation with a maximum 49.4 % inhibition observed at 10 μM (MZE vs. vehicle, respectively 1,614 ± 628 vs. 3,279 ± 281 pg of TXB~2~per 200,000 microglia per 70 min, P \> 0.05, n = 3). Furthermore, as shown in Fig. [3E](#F3){ref-type="fig"}, MZE inhibited PMA-stimulated O~2~^-^generation with a maximum 26.3 % inhibition observed at 10 μM (MZE vs. vehicle, respectively 8.5 ± 2.1 vs.10.8 ± 0.6 nmol of O~2~^-^per 200,000 microglia per 70 min, P \> 0.05, n = 3).

As shown in Fig. [2E](#F2){ref-type="fig"}, MZE had limited effect on OPZ-stimulated TXB~2~generation, with a maximum 43.1 % inhibition at 10 μM (MZE vs. vehicle, respectively 2,594 ± 646 vs. 4,504 ± 308 pg of TXB~2~per 200,000 microglia per 70 min, P \> 0.05, n = 2). Similarly, as depicted in Fig. [3E](#F3){ref-type="fig"}, MZE did not affect OPZ-stimulated O~2~^-^generation even at 10 μM.

As shown in Fig [2E](#F2){ref-type="fig"} and [3E](#F3){ref-type="fig"}, cytotoxicity of MZE to microglia measured as LDH release was low even at 10 μM (MZE vs. vehicle, respectively 20 ± 6.7 % vs. 19.8 ± 7.7 % of total LDH released by 0.1 % Triton X-100 treated-microglia, P \> 0.05, n = 5).

Effect of manzamine F on LPS-activated neonatal brain microglia TXB~2~, O~2~^-^and LDH release
----------------------------------------------------------------------------------------------

MZF differs from MZA in having a saturated ketone functionality in the eight-membered amine ring and hydroxylation at the C-8 position of the β-carboline ring system (Fig. [1](#F1){ref-type="fig"}). As shown in Fig. [2F](#F2){ref-type="fig"}, MZF did not inhibit PMA-stimulated TXB~2~generation. In the presence of 10 μM MZ, TXB~2~release was 104.1 ± 24.7 % of control TXB~2~generation (MZF vs. vehicle, respectively 3,202 ± 1,139 vs. 3,279 ± 281 pg of TXB~2~per 200,000 microglia per 70 min, P \> 0.05, n = 3). Similarly, as shown in Fig. [3F](#F3){ref-type="fig"}, MZF did not inhibit PMA-stimulated O~2~^-^release. In the presence of 10 μM MZF, O~2~^-^release was 113 ± 14.5 % of control O~2~^-^generation (MZF vs. vehicle, respectively 12.8 ± 1.6 vs. 10.8 ± 0.6 nmol of O~2~^-^per 200,000 microglia per 70 min, P \> 0.05, n = 3).

As shown in Fig. [2F](#F2){ref-type="fig"}, MZF effect on OPZ-stimulated TXB~2~generation was weak, with a non-statistically significant 26.2 % inhibition at 10 μM (MZF vs. vehicle, respectively 3,317 ± 121 vs. 4,504 ± 308 pg of TXB~2~per 200,000 microglia per 70 min, P \> 0.05, n = 2). Similarly, as depicted in Fig. [3F](#F3){ref-type="fig"}, MZF was minimally effective in inhibiting OPZ-stimulated O~2~^-^generation, only a non-statistically significant 15.7 % inhibition observed at 10 μM.

As shown in Fig. [2F](#F2){ref-type="fig"} and [3F](#F3){ref-type="fig"}, cytotoxicity of MZF to neonatal brain microglia measured as LDH release was low even at 10 μM (MZF vs. vehicle, respectively 19 ± 7.2 % vs. 19.8 ± 7.7 % of total LDH released by 0.1 % Triton X-100 treated-microglia, n = 5).

Effect of manzamine A, B, C, D, E and F on hypoxanthine-xanthine oxidase generated O~2~^-^
------------------------------------------------------------------------------------------

In order to determine a potential scavenging effect of MZA, B, C, D, E and F on O~2~^-^, a standard hypoxanthine-xanthine oxidase system was used as a cell-free source of O~2~^-^\[[@B21]\]. As shown in Fig. [4](#F4){ref-type="fig"}, O~2~^-^generation by incubation of purified xanthine oxidase with hypoxanthine was abolished by superoxide dismutase. Furthermore, DMSO, the vehicle used to prepare the manzamines, did not affect O~2~^-^formation (control vs. DMSO, respectively 12.3 ± 2.3 vs. 12 ± 1.1 nmoles/30 min, n = 2, P \> 0.05). Similarly, MZA, B, and E did not significantly affect O~2~^-^generation (MZA, B, E vs. control, respectively, 15.3 ± 4.4, 15.3 ± 2.4, 16.3 ± 2.2 vs. 12 ± 1.1 nmoles/30 min, n = 2, P \> 0.05). In contrast, MZC, D and F appeared to enhance O~2~^-^formation (MZC, D, F vs. control, respectively 20.7 ± 3.1, 22.2 ± 2, 20.1 ± 3.6 vs. 12 ± 1.1 nmoles/30 min, n = 2, P \< 0.05 (MZC, F), P \< 0.01 MZD). Thus we conclude that the inhibition of either PMA or OZ stimulated-O~2~^-^release from LPS-activated microglia by the manzamines was not the result of a direct O~2~^-^scavenging effect.

![**Differential effect of manzamine A, B, C, D, E and F and superoxide dismutase on hypoxanthine-xanthine oxidase system-generated O~2~^-^.**Cell-free source of O~2~^-^was generated by a standard hypoxanthine-oxidase system as described in *Materials and Methods*. Data are expressed as O~2~^-^released (nmoles O~2~^-^/30 min) and correspond to the mean ± SD of 2 representative experiments in duplicate. \* P \< 0.05, \*\* P \< 0.01 versus control.](1471-2210-5-6-4){#F4}

Discussion
==========

The important role of neuroinflammation and glial activation in the pathogenesis of brain disorders has progressively been established \[[@B1],[@B2],[@B22]\]. Because *in vitro*LPS-activated microglia appear to mimic the functions of activated microglia found in neuroinflammatory conditions *in vivo*\[[@B2],[@B23]\], we used LPS-activated rat microglia as a relevant *in vitro*paradigm to search for marine natural products that may modulate the enhanced release of TXB~2~and O~2~^-^from activated microglia \[[@B24]\]. Using this *in vitro*model we have previously communicated that MZA, a secondary metabolite isolated from the Okinawan marine sponge *Haliclona*sp\[[@B10]\], inhibited TXB~2~and O~2~^-^generation by microglia \[[@B18]\]. The current study extends our initial observations, and reports a structure-activity relationship study with manzamines A, B, C, D, E and F on both PMA and OPZ-stimulated release of TXB~2~and O~2~^-^from LPS-activated rat neonatal microglia.

Members of the eicosanoid family (i.e. prostaglandins, leukotrienes and thromboxanes) are important mediators of inflammation that would appear to be play a causative role in the pathogenesis of several CNS disorders \[[@B25]-[@B27]\]. Increased levels of eicosanoids have been observed in neurodegenerative disorders such as amyotrophic lateral sclerosis \[[@B28]\], multiple sclerosis \[[@B29]\], ischemia and seizures \[[@B30]\], prion diseases \[[@B31]\], human immunodeficiency virus-associated dementia \[[@B32]\] and Alzheimer\'s disease \[[@B33]\]. Following the seminal observation that microglia release eicosanoids \[[@B34]\], numerous studies have increasingly supported the notion that activated brain macrophages may be the main source of both prostaglandins \[[@B33],[@B35]-[@B39]\] and thromboxanes \[[@B23],[@B37],[@B39],[@B40]\] in these neurodegenerative diseases. Thus modulation of microglia enhanced prostanoid synthesis has been investigated as a potential drug therapeutic approach for intervention in neuroinflammatory disorders of the CNS \[[@B36],[@B41],[@B42]\]. One possible approach to diminish enhanced eicosanoid production has been to search for inhibitors of signal transduction pathways involved in eicosanoid synthesis in activated microglia \[[@B42]\]. In our study, we used PMA and OPZ, agonists known to activate p44/42 and p38 mitogen-activated protein kinases in microglia \[[@B43]\], to target distinct signal transduction pathways that cause TXB~2~release in rat neonatal microglia activated by an *in vitro*exposure to 0.3 ng/mL of LPS for 17 hours \[[@B23]\]. As shown in Fig. [2](#F2){ref-type="fig"}, the 6 marine-derived manzamine analogs attenuated PMA-stimulated TXB~2~generation differentially and in the following order of decreasing potency: MZA\>MZD\>MZB \>MZC\>MZE and F. In contrast, the manzamine analogs inhibited OPZ-stimulated TXB~2~generation with reduced potency: MZB\>MZA\>MZC\>MZD, MZE and MZF. Thus, with the exception of MZB and MZC which modulated both PMA and OPZ-stimulated TXB~2~release with similar potency, MZA, MZD, MZE and MZF inhibited TXB~2~release with lower potency when OPZ was used as an agonist.

It is interesting to compare our differential results with the MZA, B, C, D, E, and F with those reported for other agents that have been shown to modulate microglia eicosanoid release by targeting the cyclooxygenase I and II enzymes which are expressed in activated rat and human microglia \[[@B35],[@B44]\]. PGE~2~and TXB~2~synthesis that occurs concomitantly with LPS-induced activation of rat \[[@B38],[@B45],[@B46]\] and human microglia \[[@B35]\], has been shown to be attenuated by nonsteroidal anti-inflammatory drugs (NSAIDs) with differing activities towards the two isoforms of COX. Thus, LPS-induced microglia PGE~2~synthesis was reduced by COX-1 inhibitors: acetylsalicylic acid (aspirin) (IC~50~= 3.12--10 μM) \[[@B38],[@B46]\], flurbiprofen (apparent IC~50~= 100 nM) \[[@B45]\] and indomethacin (apparent IC~50~= 1 nM) \[[@B38]\], and the COX-2 inhibitor NS-398 (apparent IC~50~= 1--5 nM) \[[@B38]\]. Even though NSAIDs have been reported to attenuate neurotoxicity *in vitro*\[[@B47]\] and neuroinflammation in animal models \[[@B48]-[@B50]\], an important caveat is the fact that determining the best NSAIDs for clinical neurodegenerative disease management appears to remain a matter of considerable debate in view of their well known adverse effects \[[@B51]-[@B53]\]. Thus, although the molecular mechanism by which the manzamines inhibit TXB~2~release in LPS-activated cells remains currently undetermined, MZA inhibited PMA-stimulated eicosanoid generation *in vitro*with potency similar to that of the COX-1 inhibitor indomethacin \[[@B38]\], potency that was higher than that of other NSAIDs that have been reported to modulate enhanced eicosanoid release in both activated rat and human microglia \[[@B35],[@B38],[@B45],[@B46]\].

The involvement of reactive oxygen species (ROS) has been documented in CNS pathologies, such as Parkinson\'s disease, Alzheimer\'s disease, Huntington\'s disease, Down\'s syndrome, cerebral ischemia and reperfusion, amyotrophic lateral sclerosis, multiple sclerosis and meningitis \[[@B54]\]. Prolonged exposure to ROS may potentially damage neurons, particularly their synapses \[[@B55]\] as well as oligodendrocytes, the myelin producing cell of the CNS \[[@B56]\] by overriding normal CNS antioxidant defense mechanisms, e.g. superoxide dismutase, catalase, glutathione-S-transferase, glutathione peroxidase, permanently affecting cellular function \[[@B57]\]. Thus the mechanism of ROS generation by CNS leukocytes, i.e. infiltrating neutrophils and monocytes as well as resident microglia production of O~2~^-^, hydrogen peroxide and nitric oxide in CNS, has received considerable attention since the mid-1980s \[[@B2]\]. In fact, during the past 18 years, numerous research groups have shown that O~2~^-^may be generated by microglia isolated from rat, mice, hamsters, dogs, swine and humans, when stimulated with a variety of agonists such as phorbol ester, opsonized zymosan, calcium ionophore, antiviral antibodies, antibody-coated red blood cells and myelin (reviewed in \[[@B2]\]). We and others have hypothesized that rather than scavenge ROS with antioxidants, the modulation of the signal transduction mechanism leading to microglia ROS generation might be putatively a better therapeutic strategy to turn off or reduce ROS generation that could lead to neuronal injury \[[@B2],[@B58],[@B59]\]. As depicted in Fig. [3](#F3){ref-type="fig"}, the manzamine analogs attenuated PMA-stimulated O~2~^-^generation in the following order of decreasing potency: MZD\>MZA\>MZB\>MZC\>MZE and MZF. In contrast, and similarly to their weaker effect on OPZ-stimulated TXB~2~generation, all the manzamine analogs modulated OPZ-stimulated O~2~^-^generation with lower potency: MZB\>MZC\>MZA, MZD, MZE and MZF. Interestingly, as shown in Fig. [4](#F4){ref-type="fig"}, the effect of MZD, A, B and C on PMA-stimulated O~2~^-^formation was not the result of any detectable scavenging O~2~^-^, because none of the manzamines inhibited a standard hypoxanthine-xanthine oxidase system that was used as a cell-free source of O~2~^-^. Thus, although the exact mechanism by which the manzamines modulate O~2~^-^release by microglia remains currently undetermined, we have demonstrated that these compounds clearly modulate the signal transduction pathway that PMA triggers in microglia and ultimately leads to O~2~^-^generation.

It is interesting to compare our differential results with the MZD, A, B and C with those reported for other agents that modulate PMA-stimulated O~2~^-^generation in microglia. Interestingly, MZD, A, B and C demonstrated higher potency than three clinically available agents shown to inhibit PMA-stimulated O~2~^-^generation: propentofylline, a selective phosphodiesterase inhibitor (IC~50~\>100 μM) \[[@B60]\], cabergoline, a potent and selective agonist of D2-dopamine receptors (IC~50~\>100 μM) \[[@B59]\], and nicergoline, an ergoline derivative used for cerebrovascular diseases (IC~50~= 10--15 μM) \[[@B58]\]. It is noteworthy that these agents have been proposed to confer protective effects against neurodegenerative diseases which may involve O~2~^-^release by activated rat microglia.

In order to determine if the effect of the manzamines on PMA or OPZ-triggered TXB~2~and O~2~^-^generation was either pharmacological or toxic, we investigated LDH release from LPS-activated rat neonatal microglia. LDH has extensively been used as a marker for cell cytotoxicity \[[@B61]\]. The results from our investigation appear to demonstrate that the manzamine analogs clearly differed in their effect on LDH release from LPS-primed microglia: MZA, MZE and MZF generated less than 50% of maximal LDH release at 10 μM, and thus were the least toxic analogs; MZB and MZC induced greater than 50% of LDH release at 10 μM; while MZD showed greater than 50% of LDH release at 0.1 μM when PMA rather than OPZ was used as an agonist, thus its toxicity contrasted with the other analogs tested. Thus even though MZD inhibited PMA-stimulated O~2~^-^generation with slightly higher potency than MZA, because MZD caused concomitant LDH release at low concentrations (0.1 μM), the nature of the inhibitory effect on PMA-triggered O~2~^-^and TXB~2~release, either toxic or pharmacological, remains currently unresolved. In summary, the *in vitro*studies described herein suggest that MZA is the most potent manzamine analog of the series investigated because both PMA-stimulated O~2~^-^and TXB~2~were potently inhibited with the *lowest*concomitant release of LDH.

It is of interest to consider the results of our structure-activity relationship (SAR) study with the manzamines, alkaloids characterized by a complex heterocyclic ring system attached to the C-1 of the β-carboline moiety. From the SAR perspective, the potent effect of MZA and D hydrochloride salts on PMA-stimulated O~2~^-^and TXB~2~suggests that the solubility or ionic forms are contributing factors to their bioactivity. Furthermore, the fused 13-membered macrocyclic and octahydroisoquinoline ring system, and any substitutions in these rings would appear to be less important for their *in vitro*activity. Finally, changes such as saturation or oxidation of the β carboline or the 8-membered amine ring tended to decrease bioactivity in both O~2~^-^and TXB~2~assays.

Taken together, our current data demonstrates that the most potent and least toxic manzamine analog, namely MZA, was less effective in attenuating O~2~^-^and TXB~2~from LPS-activated microglia when the triggering agonist was OPZ rather than PMA. Similar differential effects between PMA and OPZ-triggered signaling have been observed with other natural products \[[@B62]\]. Furthermore, the current data suggest the following on the as yet undefined mechanism of action of MZA: Firstly, that the MZA molecular target plays a critical role in O~2~^-^and TXB~2~generation initiated by PMA upon binding to PKC \[[@B63],[@B64]\] and activation of the p44/42 mitogen-activated protein kinase signaling pathway \[[@B43]\]; Secondly, that the MZA molecular target probably plays a less critical role in O~2~^-^and TXB~2~release elicited by OPZ, a ligand of the microglial cell surface complement receptor 3 shown to activate the p38 mitogen-activated protein kinase signaling pathway \[[@B43]\]. Studies to determine which element is targeted by MZA in the p38 and/or p44/42 mitogen-activated protein kinase pathways in LPS-activated rat microglia are currently underway in our laboratory.

Conclusion
==========

Our present results provide the first experimental evidence to support the hypothesis that the marine-derived β-carboline alkaloid manzamines differentially modulate both O~2~^-^and TXB~2~generated by *E. coli*LPS-activated rat neonatal microglia. Additional conclusions are the following: Firstly, SAR studies demonstrated that at *in vitro*concentrations that were non-toxic to *E. coli*LPS-activated rat neonatal microglia, MZA was the most potent inhibitor of O~2~^-^and TXB~2.~Secondly, although the mechanism by which MZA inhibited PMA-stimulated TXB~2~generation *in vitro*is as yet unclear, its potency was similar to the COX-1 inhibitor indomethacin \[[@B38]\], and thus higher than other NSAIDs reported to modulate enhanced eicosanoid release in both activated rat and human microglia \[[@B35],[@B38],[@B45],[@B46]\]. Thirdly, although the mechanism by which MZA inhibited PMA-stimulated O~2~^-^generation *in vitro*remains undetermined, MZA was more potent than propentofylline, a selective phosphodiesterase inhibitor, cabergoline, a potent and selective agonist of D2-dopamine receptors and nicergoline, an ergoline derivative used for cerebrovascular diseases, compounds which have been proposed to confer protective effects against neurodegenerative diseases by affecting O~2~^-^release by activated rat microglia. Fourthly, SAR studies which demonstrated that the ionic forms are a contributing factor to the bioactivity of the complex manzamine heterocyclic ring system attached to a β-carboline moiety may explain the potent effect of MZA and D hydrochloride salts on PMA-stimulated O~2~^-^and TXB~2~. Interestingly, the fused 13-membered macrocyclic amine and octahydroisoquinoline ring system, as well as substitutions in these rings appeared to be a non-factor for the *in vitro*activity of the manzamines. Finally, the reported pharmacokinetic properties and the lack of significant *in vivo*toxicity \[[@B14]\] of MZA, a β-carboline alkaloid whose complete synthesis has been reported \[[@B11]\], would suggest that MZA is a prime candidate for further investigation of its potential utility as a pharmacophore from which new and novel therapeutic agents for neuroinflammatory diseases might be developed.

Methods
=======

Reagents
--------

LPS B (*Escherichia coli*026:B6) was obtained from Difco Laboratories (Detroit, MI); Wright Giemsa stain (modified), ferricytochrome c type III (from horse heart) (FCC), superoxide dismutase (from bovine liver), phorbol 12-myristate 13-acetate (PMA), zymosan and dimethyl sulphoxide (DMSO) were obtained from Sigma Chemical Co. (St. Louis, MO). PMA was maintained at -80°C as a 10 mM stock solution in DMSO. Opsonized zymosan (OPZ) was maintained at -20°C in a stock solution of 15 mg/ml in PBS and prepared as described \[[@B65]\]. Dulbecco\'s modified Eagle medium (DMEM) with high glucose (4,500 mg/l), Hank\'s balanced salt solution (HBSS), penicillin (P), streptomycin (S), trypsin (0.25%)-EDTA (1 mM) and trypan blue were purchased from GIBCO-BRL (Grand Island, NY); certified heat-inactivated fetal bovine serum (FBS) was obtained from Hyclone (Logan, UT); a LPS stock of 1 mg/ml was prepared in a 0.9% sodium chloride nonpyrogenic solution from Baxter Healthcare Corp. (Toronto, ONT, Canada) and then diluted with DMEM plus 10% FBS plus P and S to the appropriate concentration used in our experiments. Both the LPS stock solution \[10 ng/ml\] and dilutions were stored at -80°C, thawed prior to each experiment and discarded after use.

LPS containment
---------------

To inactivate extraneous LPS, all glassware and metal spatulas were baked for 4 hours at 180°C. Sterile and LPS-free 75- and 162-cm^2^vented cell culture flasks, 24-well flat-bottom culture clusters, 96-well cell culture clusters and disposable serological pipettes were purchased from Costar Corporation (Cambridge, MA), while polystyrene cell culture dishes (60 × 15 mm) were obtained from Corning Glass Works (Corning, NY). Sterile and LPS-free Eppendorf Biopur pipette tips were purchased from Brinkmann Instruments, Inc. (Westbury, NY).

Manzamines A, B, C, D, E and F
------------------------------

Manzamine A (MZA) was isolated from a marine sponge species of the genus *Haliclona*collected off Manzamo, Okinawa in waters at a depth of 30 m in April 1985 \[[@B10]\]. Manzamine B (MZB), manzamine C (MZC) and manzamine D (MZD), were isolated from a sponge of the genus *Amphimedon*collected by SCUBA off Manzamo, Okinawa \[[@B66]\]. Manzamine E (MZE) and manzamine F (MZF) were isolated from a sponge species of the genus *Xestospongia*collected off the coast of Miyako Island, Okinawa in June 1986 \[[@B67]\]. All manzamines were dissolved in DMSO to prepare a 10 mM stock and stored at -80°C prior to use in the experiments.

Isolation and culture of rat neonatal microglia
-----------------------------------------------

All experiments were performed with adherence to the National Institutes of Health guidelines on the use of experimental animals and with protocols approved by Midwestern University\'s Research and Animal Care Committee. To isolate rat neonatal microglia, cerebral cortices of 1--2 day-old Sprague-Dawley rats purchased from Harlan (Indianapolis, IN) were surgically removed and placed in cold DMEM + 10% FBS + 120 U/ml P and 12 μg/ml S, the meninges carefully removed, and brain tissue minced and dissociated with trypsin-EDTA at 36°C for 3--5 min. The mixed astroglial cell suspension was plated in either 75- or 162-cm^2^vented cell culture flasks with DMEM medium supplemented with 10% FBS + 120 U/ml P + 12 μg/ml S and grown in a humidified 5% CO~2~incubator at 36°C for 12--14 days. On day 14 and every 3--4 days thereafter, microglia were detached using an orbital shaker (150 rpm, 0.5 hours, 36°C, 5% CO~2~), centrifuged (400 × g, 25 min, 4°C), and microglia number and viability assessed by trypan blue exclusion. Microglia were characterized as described earlier \[[@B23]\]. Depending on the particular experimental protocol (see below), microglia averaging greater than 95% viability were plated in 24-well cell culture clusters, with DMEM supplemented with 10% FBS + 120 U/ml P + 12 μg/ml S, and placed in a humidified 5% CO~2~incubator at 36°C 18--24 hours prior to the experiments.

Experimental protocol to study the effect of manzamines A -- F on microglia release of TXB~2~and O~2~^-^
--------------------------------------------------------------------------------------------------------

To study the effects of manzamines A, B, C, D, E and F on the generation of TXB~2~and O~2~^-^, rat neonatal microglia (2 × 10^5^cells/24-well cell culture clusters) were treated to the following protocol. Seventeen hours prior to the experiments, microglia cells were treated with LPS (0.3 ng/ml) in a final volume of 1 ml of DMEM supplemented with 10% FBS + 120 U/ml P + 12 μg/ml. Thereafter the media was removed and replaced with 1 ml warm HBSS, one of the manzamines (0.1--10 μM final concentration) or vehicle (DMSO) was added, and the microglia incubated for fifteen minutes in a humidified 5% CO~2~incubator at 35.9°C. After the fifteen minute preincubation period with either manzamines or vehicle, PMA (1 μM) or OPZ (0.5 mg/mL) was added and microglia incubated for 70 minutes in a humidified 5% CO~2~incubator at 35.9°C in the presence of the manzamines or vehicle. The final concentration of DMSO did not affect microglia viability or LDH release. O~2~^-^, TXB~2~and lactate dehydrogenase (LDH) release were assayed as described below.

Assay for TXB~2~
----------------

Following the incubation of LPS-activated microglia with HBSS, manzamines or vehicle as explained above, PMA- (1 μM) or OPZ- (0.5 mg/mL)triggered TXB~2~generation in the culture supernatants was measured using immunoassays (Cayman Chemical, Ann Arbor, MI) as indicated by the manufacturer\'s protocol. Results were expressed as pg/mL produced after 70 min of PMA or OPZ stimulation.

Assay for O~2~^-^
-----------------

O~2~^-^generation was determined by the SOD-inhibitable reduction of FCC \[[@B23]\]. Briefly, PMA (1 μM) or OPZ (0.5 mg/mL)- triggered O~2~^-^release from LPS-activated microglia was measured in the presence of FCC (50 μM) and HBSS, with or without SOD (700 Units) which inhibited \>95% of FCC reduction, during the 70 min incubation described above. All experimental treatments were run in triplicate and in a final volume of 1 ml. Changes in FCC absorbance were measured at 550 nm using a Beckman DU-650 spectrophotometer. Differences in the amount of reduced FCC in the presence and absence of SOD were used to determine O~2~^-^generation and expressed in nmol by employing the molecular extinction coefficient of 21.0 × 10^3^M^-1^cm^-1^.

Experimental protocol to study the effect of manzamines on superoxide anion by the hypoxanthine-xanthine oxidase system
-----------------------------------------------------------------------------------------------------------------------

A standard hypoxanthine-xanthine oxidase system was used as a cell-free source of O~2~^-^. O~2~^-^was generated by incubation of purified xanthine oxidase (0.02 Units/ml) with hypoxanthine (1.5 mM) at 37°C \[[@B21]\]. O~2~^-^formation was assessed spectrophotometrically as the increase in absorbance at 550 nm associated with the SOD (30 U/mL)-inhibitable reduction FCC (50 μM) as described above for rat microglia O~2~^-^generation and expressed in nmoles/30 minutes.

Lactate dehydrogenase assay
---------------------------

Lactate dehydrogenase (LDH) release from microglia was determined spectrophotometrically as described elsewhere \[[@B9]\]. Microglia LDH release was expressed as a percentage of total LDH. Total LDH resulted from 0.1% Triton X-100-lysed microglia cells (intracellular LDH) plus LDH released to the extracellular medium.

Statistical analysis of the data
--------------------------------

Data were analyzed with the Prism^®^software package purchased from GraphPad (San Diego, CA.). One-way analysis of variance followed by Dunnett\'s test was performed on all sets of data. Manzamine-treated groups were compared with the vehicle-treated group, shown as 0 or control in the corresponding figures. Differences were considered statistically significant at p \< 0.05 and reported in each figure legend.
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